- Home
- / Cue Biopharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cue Biopharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.7
2024-10-29
Market Capitalization
$107.3 M
2024-10-29
Revenue
$9.3 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 18, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.5M | 3.2M | 14.9M | 1.2M | 5.5M | 9.3M | ||||
| General and administrative expense | 425.1K | 2.0M | 4.3M | 11.3M | 12.7M | 14.7M | 17.3M | 16.2M | 16.7M | 14.6M |
| Operating expense total | 1.9M | 7.7M | 23.2M | 39.8M | 40.2M | 48.2M | 54.7M | 57.5M | 50.9M | |
| EBIT | (1.9M) | (7.7M) | (23.2M) | (38.7M) | (36.8M) | (45.0M) | (43.7M) | (53.2M) | (52.1M) | (41.5M) |
| EBIT margin, % | -1063.2% | -1428.0% | -4274.3% | -949.9% | -446.9% | |||||
| Interest income | 52.0 | 35.0 | 376.0K | |||||||
| Interest expense | 418.7K | 463.9K | 45.9K | 713.8K | 130.0K | 100.0K | ||||
| Pre tax profit | (38.2M) | (36.3M) | (44.6M) | (43.7M) | (53.0M) | |||||
| Income tax expense | 825.0K | 412.5K | 206.3K | 495.0K | ||||||
| Net Income | (1.9M) | (7.7M) | (23.2M) | (39.0M) | (36.7M) | (44.8M) | (44.2M) | (53.0M) | (50.7M) | (40.7M) |
| EPS | (0.3) | (1.0) | (2.2) | (1.5) | (1.1) | (0.7) |